Clinical roles of nuclear matrix protein 22 and Atyp.C parameter in diagnosis of bladder cancer

doi:10.3969/j.issn.1673-8640.2023.08.006

Abstract

Abstract:

Objective To investigate the clinical role of the combined determination of nuclear matrix protein 22（NMP22） and atypical cells（Atyp.C） parameter using urinary sediment analyzer in the diagnosis of bladder cancer. Methods Totally，3 288 patients with NMP22 and urinary sediment determinations in Jing'an District Shibei Hospital were enrolled from October 2021 to September 2022. There were 97 patients with bladder cancer（bladder cancer group，97 males） and 3 191 patients with other urinary system diseases（total control group，1 212 males and 1 979 females）. A total of 1 212 male patients with urinary system diseases were used as male control group. Receiver operating characteristic（ROC） curve was used to evaluate the efficiency of each index in the diagnosis of bladder cancer. Results The positive rate of NMP22 and the fluorescence intensity of Atyp.C in bladder cancer group were higher than those in male control group and total control group（P<0.001）. ROC curve analysis results showed that the areas under curves（AUC） of NMP22 and Atyp.C fluorescence intensity single and combined determinations in the diagnosis of bladder cancer were 0.794，0.757 and 0.867，respectively，when the male control group was taken as control group. When the total control group was used as control group，the AUC of NMP22 and Atyp.C fluorescence intensity single and combined determinations were 0.787，0.752 and 0.861，respectively. Conclusions In the diagnosis of bladder cancer，NMP22 has a high sensitivity，Atyp.C has a high specificity，and the combined determination can improve the diagnostic efficiency.

Key words: Nuclear matrix protein 22, Atypical cell, Urinary sediment analyzer, Bladder cancer

CLC Number:

R446.1

WANG Yuemei, LI Lei. Clinical roles of nuclear matrix protein 22 and Atyp.C parameter in diagnosis of bladder cancer[J]. Laboratory Medicine, 2023, 38(8): 738-741.

Figures/Tables 5

References 14

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. DOI URL
[2]	NGUYEN C T, JONES J S. Defining the role of NMP22 in bladder cancer surveillance[J]. World J Urol, 2008, 26(1):51-58. DOI PMID
[3]	KUNDAL V K, PANDITH A A, HAMID A, et al. Role of NMP22 bladder check test in early detection of bladder cancer with recurrence[J]. Asian Pac J Cancer Prev, 2010, 11(5):1279-1282.
[4]	LENIS A T, LEC P M, CHAMIE K, et al. Bladder cancer:a review[J]. JAMA, 2020, 324(19):1980-1991. DOI URL
[5]	STEINER H, BERGMEISTER M, VERDORFER I, et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers[J]. BJU Int, 2008, 102(3):291-296. DOI PMID
[6]	OYAERT M, MAGHARI S, SPEECKAERT M, et al. Improving clinical performance of urine sediment analysis by implementation of intelligent verification criteria[J]. Clin Chem Lab Med, 2022, 60(11):1772-1779. DOI PMID
[7]	CHEN Y, ZHANG Z, LIN Z, et al. Sysmex UF-5000 automatic urine sediment analyzer can improve the accuracy of epithelial cell detection[J]. Ann Clin Lab Sci, 2021, 51(4):562-569. PMID
[8]	马重, 林建水, 曾蜀雄, 等. 膀胱癌无创性早期诊断标志物的研究进展[J]. 上海医学, 2015, 38(4):347-350.
[9]	MATI Q, QAMAR S, ASHRAF S, et al. Tissue nuclear matrix protein expression 22 in various grades and stages of bladder cancer[J]. J Coll Physicians Surg Pak, 2020, 30(12):1321-1325. DOI PMID
[10]	YUAN L, GERO M, ZIA S, et al. Cyto-histo correlation and false-negative urine:before and after the Paris system for reporting urinary cytology[J]. Diagn Cytopathol, 2022, 50(8):404-410. DOI URL
[11]	REN C, WANG X, YANG C, et al. Investigation of Atyp.C using UF-5000 flow cytometer in patients with a suspected diagnosis of urothelial carcinoma:a single-center study[J]. Diagn Pathol, 2020, 15(1):77. DOI
[12]	SCHMITZ-DRÄGER B J, DROLLER M, LOKESHWAR V B, et al. Molecular markers for bladder cancer screening,early diagnosis,and surveillance:the WHO/ICUD consensus[J]. Urol Int, 2015, 94(1):1-24. DOI URL
[13]	韩苏军, 张思维, 陈万青, 等. 中国膀胱癌发病现状及流行趋势分析[J]. 癌症进展, 2013, 11(1):89-95.
[14]	宋东奎, 张志永. 腺性膀胱炎诊断2 228例文献分析[J]. 中国误诊学杂志, 2005, 5(16):89-90.

组别	例数	年龄/岁	NMP22阳性/[例（%）]	Atyp.C荧光强度
膀胱癌组	97	60.0（62.0~68.0）^*#	73（75.3）^*#	1.30（0~3.15）^*#
男性对照组	1 212	66.0（47.0~70.0）	199（16.4）	0
总对照组	3 191	65.0（55.0~71.0）	567（17.8）	0

组别	例数	年龄/岁	NMP22阳性/[例（%）]	Atyp.C荧光强度
膀胱癌组	97	60.0（62.0~68.0）^*#	73（75.3）^*#	1.30（0~3.15）^*#
男性对照组	1 212	66.0（47.0~70.0）	199（16.4）	0
总对照组	3 191	65.0（55.0~71.0）	567（17.8）	0

TNM分期	例数	NMP22阳性/ [例（%）]	Atyp.C荧光强度
Ⅰ期	42	24（57.1）	0.00（0.00~1.25）
Ⅱ期	30	25（83.3）	2.25（0.00~3.98）
Ⅲ期	25	24（96.1）	2.90（1.75~4.90）
统计值		14.23	26.48
P值		0.001	<0.001

TNM分期	例数	NMP22阳性/ [例（%）]	Atyp.C荧光强度
Ⅰ期	42	24（57.1）	0.00（0.00~1.25）
Ⅱ期	30	25（83.3）	2.25（0.00~3.98）
Ⅲ期	25	24（96.1）	2.90（1.75~4.90）
统计值		14.23	26.48
P值		0.001	<0.001

项目	AUC（95%CI^①）	最佳临界值	敏感性	特异性	Youden指数
NMP22	0.794（0.743~0.845）	1^②	75.3	83.6	0.589
Atyp.C荧光强度	0.757（0.692~0.821）	0.59	55.7	97.6	0.533
联合检测	0.867（0.821~0.913）	0.884 9	85.6	81.5	0.671